BioPharmSignal logoBioPharmSignal

Biotech News

Tango Therapeutics Announces Proposed $500 Million Public Offering

Tango Therapeutics (TNGX)Tango Therapeutics2026-06-25 13:46 ESTFinancing

BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the launch of an underwritten public offering (the

Open original release

Related news

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Appoints Robert Azelby to Board of Directors

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Appoints Sung Lee to Board of Directors

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences

View all latest news

Tango Therapeutics

Tango Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

TNGXTango Therapeutics2026-06-26 05:14 EST

Tango Therapeutics Appoints Robert Azelby to Board of Directors

TNGXTango Therapeutics2026-06-26 05:14 EST

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

TNGXTango Therapeutics2026-06-26 05:14 EST

Tango Therapeutics Announces Proposed $500 Million Public Offering

TNGXTango Therapeutics2026-06-26 05:14 EST

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

TNGXTango Therapeutics2026-06-26 05:14 EST

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States